quantisnow
FeedTopReportsPricing
⌘K
Live feed
09:02:59·815d
NEWSRelease
Apple Inc. logo
Amazon.com Inc. logo
Global X Robotics & Artificial Intelligence ETF logo
+13

AI, Biotech, Energy Sectors Expect M&A Revival For 2024

AAPL· Apple Inc.AMZN· Amazon.com Inc.BOTZ· Global X Robotics & Artificial Intelligence ETFCOP· ConocoPhillipsCVX· Chevron CorporationGOOGL· Alphabet Inc.
TechnologyConsumer DiscretionaryEnergy
Original source

Companies

  • AAPL
    Apple Inc.
    Technology
  • AMZN
    Amazon.com Inc.
    Consumer Discretionary
  • BOTZ
    Global X Robotics & Artificial Intelligence ETF
    n/a
  • COP
    ConocoPhillips
    Energy
  • CVX
    Chevron Corporation
    Energy
  • GOOGL
    Alphabet Inc.
    Technology
  • HES
    Hess Corporation
    Energy
  • IBB
    iShares Nasdaq Biotechnology Index Fund
    n/a
  • KRYS
    Krystal Biotech Inc.
    Health Care
  • MSFT
    Microsoft Corporation
    Technology
  • NVDA
    NVIDIA Corporation
    Technology
  • PXD
    Pioneer Natural Resources Company
    Energy
  • REGN
    Regeneron Pharmaceuticals Inc.
    Health Care
  • VRTX
    Vertex Pharmaceuticals Incorporated
    Health Care
  • VTYX
    Ventyx Biosciences Inc.
    Health Care
  • XOM
    Exxon Mobil Corporation
    Energy

Recent analyst ratings

  • Apr 21XOMUpdateWolfe Research-
  • Apr 21MSFTUpdateCitigroup$600.00
  • Apr 20GOOGLUpdateKeyBanc Capital Markets$380.00
  • Apr 20AMZNUpdateKeyBanc Capital Markets$325.00
  • Apr 17AMZNUpdateTruist$285.00
  • Apr 17XOMUpdateBNP Paribas Exane$165.00

Related

  • PR11h
    Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.
  • PR14h
    Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.
  • PR1d
    Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)
  • PR1d
    Press Release: Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
  • INSIDER2d
    SEC Form 4 filed by Jassy Andrew R
  • PR2d
    Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial
  • PR2d
    AI-Driven Video Intelligence and RF-Powered Detection Moving to the Front Line of Military Modernization
  • PR2d
    The AI Power Surge: Why Energy Infrastructure Is Becoming the Next Critical Bottleneck
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022